

- ous tumor-associated antigens expressed on solid epithelial tumors. *Hum Immunol* 1998, **50**:1-14.
6. Van der Bruggen P, Basti J, Gajewski T, Coullie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T: **A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.** *Eur J Immunol* 1994, **24**:3038-3043.
 7. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: **Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.** *J Exp Med* 1999, **191**:1669-1678.
 8. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM: **Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.** *J Immunother* 2000, **23**:487-498.
 9. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J: **Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.** *J Immunother* 2001, **24**:66-78.
 10. Nestle FO, Aljagic S, Gilliet M, Sun Y, Grabbe S, Dumme R, Burg G, Schadendorf D: **Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.** *Nat Med* 1998, **4**:328-332.
 11. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: **Immune and clinical responses in patients with metastatic melanoma to CD34⁺ progenitor-derived dendritic cell vaccine.** *Cancer Res* 2001, **61**:6451-6458.
 12. Kang X, Kawakami Y, El-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF: **Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.** *J Immunol* 1995, **155**:1343-1348.
 13. Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T: **A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.** *Int J Cancer* 1999, **80**:169-172.
 14. Tahara K, Takasako K, Sette A, Celis E, Kitano S, Akiyoshi T: **Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.** *Clin Cancer Res* 1999, **5**:2236-2241.
 15. Tanaka F, Fujie T, Tahara K, Mori M, Takasako K, Sette A, Celis E, Akiyoshi T: **Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.** *Cancer Res* 1997, **57**:4465-4468.
 16. Umamo Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H: **Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.** *Br J Cancer* 2001, **84**:1052-1057.
 17. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S: **Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.** *Blood* 2001, **97**:2903-2907.
 18. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I: **Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.** *Int J Cancer* 1999, **80**:92-97.
 19. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K: **Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.** *Anticancer Res* 2004, **24**:571-578.
 20. Kuzushima K, Hayashi N, Kimura H, Tsurumi T: **Efficient identification of HLA-A2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.** *Blood* 2001, **98**:1872-1881.
 21. Sidney J, Southwood S, Mann DL, Fernandez-Vina AA, Newman MJ, Sette A: **Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.** *Hum Immunol* 2001, **62**:1200-1216.
 22. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M: **Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A14-specific MAGE-3 peptide.** *Clin Cancer Res* 2001, **7**:23-31.
 23. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Ariyoshi T, Mori M: **Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.** *Clin Cancer Res* 2001, **7**:2277-2284.
 24. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamaguchi H: **Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.** *Int J Oncol* 2004, **24**:909-917.
 25. Smith SG, Patel PM, Porte J, Selby PJ, Jackson AM: **Human dendritic cells genetically engineered to express a melanoma polypeptide DNA vaccine induce multiple cytotoxic T-cell responses.** *Clin Cancer Res* 2001, **7**:4253-4261.
 26. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J: **Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responders to a dendritic cell-based multipptide vaccine in patients with melanoma.** *Clin Cancer Res* 2003, **9**:641-649.
 27. Khong HT, Wang QJ, Rosenberg SA: **Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.** *J Immunother* 2004, **27**:184-190.
 28. Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D: **Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.** *Int J Cancer* 2003, **103**:759-767.
 29. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO: **High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma.** *J Immunother* 2004, **27**:73-78.
 30. Suen Y, Lee SM, Aono F, Hou S, Loudovaris M, Ofstein G, Bender JG: **Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC.** *Cytotherapy* 2001, **3**:365-372.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

